New progress has been made in the pharmacological active ingredients of Lianhua Qingwen Capsules against new coronary pneumonia

Medical Network, January 26.
Recently, Professor Wu Caisheng from the School of Pharmacy of Xiamen University and Professor Chai Yifeng of the Naval Military Medical University have made new progress in the research of the pharmacologically active ingredients and mechanisms of Lianhua Qingwen Capsules in the prevention and treatment of new coronary pneumonia.
ACE2 Biochromatographic Screening of Traditional Chinese Medicine Lianhua Qingwen Capsule's Anti-COVID-19 Pharmacological Active Ingredients" was published in the top pharmacy journal "Acta Pharmaceutica Sinica"
.
Based on HRMS and intelligent non-targeted data mining technology, this study comprehensively analyzed the components of Lianhua Qingwen capsules in human plasma and urine after multiple administrations, synthesized a new ACE2 biochromatographic stationary phase, and screened Lianhua The potential ACE2 target components of Qingwen capsule extract and human urine samples
.
The experimental results showed that 85 related components of Lianhua Qingwen were successfully identified in the human body after multiple administrations, and a small part of the components were selected to verify the ACE2 binding ability through SPR analysis.
The components are amygdalin, melanin, and licorice.
Acid, forsythin A, forsythin I, rhein, aloe-emodin, etc.
all have binding affinity to ACE2
.
It is worth mentioning that these components not only show good affinity for ACE2, but also confirmed by computer-aided docking results that they can effectively bind to the contact surface of ACE2 and S protein complex.
These ACE2 binding components may effectively affect ACE2 and The binding between S proteins inhibits the new coronavirus (SARS-CoV-2), which provides experimental evidence for Lianhua Qingwen Capsules to prevent and treat new coronary pneumonia (COVID-19)
.
Lianhua Qingwen Capsule is an innovative Chinese medicine developed by combining traditional classic prescriptions and clinical practice under the guidance of TCM collateral disease theory.
It is mainly used for the treatment of colds, flu, new coronary pneumonia and other diseases
.
Since the new crown pneumonia outbreak, as in medicine one of the "three drug tripartite" effective drug treatment new crown pneumonia screened, Lianhuaqingwen capsules (granules) has been the national guard health committee and the National Traditional Chinese Medicine Administration jointly issued the "new Coronavirus Pneumonia Diagnosis and Treatment Plan" (trial version 4/5/6/7/8) and new coronary pneumonia diagnosis and treatment plans in more than 20 provinces and cities are recommended by the countryThe Drug Administration approved the treatment of "new coronavirus pneumonia mild and common", which played an important role in the treatment of patients with new coronary pneumonia and became a hot spot Chinese patent medicine for the fight against the epidemic
.
The research results published this time are the first elaboration of the research information of Lianhua Qingwen Capsule's human body composition, which provides a chemical and pharmacological theoretical basis for the study of its pharmacologically active ingredients and mechanism of action against new coronary pneumonia (COVID-19) From the perspective of the human body, it further elaborates how Lianhua Qingwen works and what ingredients play a role.
It is an extension of the experimental research and clinical evidence of Lianhua Qingwen's treatment of new coronary pneumonia
.
Previously, the research team of Academician Zhong Nanshan confirmed that Lianhua Qingwen can significantly inhibit the replication of the new coronavirus in cells, significantly reduce the expression of viral particles in the cell, and significantly inhibit the inflammatory factor TNF- caused by the new coronavirus infecting cells.
a, IL-6, MCP-1 and IP-10 genes are overexpressed
.
This study revealed the pharmacological basis of the exact efficacy of Lianhua Qingwen in COVID-19, and confirmed that Lianhua Qingwen has anti-coronavirus activity by inhibiting virus replication and inhibiting the expression of host cell inflammatory factors
.
On the basis of this research, the research results of the pharmacologically active ingredients of Lianhua Qingwen Capsules in preventing and treating new coronary pneumonia further elaborated that Lianhua Qingwen inhibits the invasion of new coronavirus by affecting the binding of S protein and cells, and is deeply molecular based on the existing cell-level evidence.
The level once again confirms the anti-coronavirus effect of Lianhua Qingwen
.
During the new crown pneumonia epidemic last year, Zhong Nanshan and other academicians joined more than 20 hospitals across the country tojointly carry out the "Prospective, randomized, controlled, multi-center clinical study on the treatment of new coronavirus pneumonia with traditional Chinese medicine Lianhua Qingwen Capsule".
The results of the study were published in "Phytomedicine" ("Phytomedicine"), a journal with a high impact factor in the field of international plant medicine
.
The results of the study show that oral administration of Lianhua Qingwen Capsules for 14 days can significantly improve the improvement rate of clinical symptoms such as fever, fatigue, and cough of new coronary pneumonia, significantly improve lung imaging lesions, shorten the duration of symptoms, increase clinical cure rate, and contain The condition of the new crown has deteriorated
.